Approximately half of men with metastatic castration-resistant prostate cancer and BRCA1 or BRCA2 mutations do not receive medications that could improve their survival.Poly (adenosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback